StemCell Therapy

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company's stock prices soar on news of a broader, more global product distribution. Prana is continuing to expand its presentation of PBT-434, while Xenetic is moving ahead with its strategic planning goals to make its product technology available to a larger geographical area.

RDI Initiates Coverage:

Prana Biotechnology Limited https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences Inc. https://ub.rdinvesting.com/news/?ticker=XBIO

Prana Biotechnology advanced 37.65% to close at $3.40 on Thursday. The stock traded in a wide range between $4.58 and $2.75 during the day on a volume of 11.95 million shares traded. The company has presented new data from its Reach2HD trial at the American Neurological Association Annual Meeting held in Baltimore. Its primary candidate drug, PBT-434, demonstrated pre-clinical evidence that the drug will help with the treatment of movement disorders of patients with Parkinson's Disease.

Prana Biotechnology, an Australian company, for the half-year period ending December 31, 2016, reported total operating expenses of $6.05 million AUD, a pre-tax income of $3.65 million AUD, and a loss of $0.68 AUD per share.

Access RDI's Prana Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences accelerated to advance 44.30% to close at $5.44 on Thursday. The stock traded between $5.61 and $3.87 on volume of 180,793 shares traded. Xenetic has been aggressively promoting its products internationally, and the rise in price is due in part to it becoming a member of the NASDAQ community on March 30th. The company has been expanding its patent portfolio to a number of countries, including Europe and the United States. Currently, their major marketable product is PolyXen technology platform. The product's IP on its PolyXen technology platform will afford protection on average for the next 10 to 12 years.

The latest financial report with period ending September 30, 2016, showed the company posting $2.25 million in operating expenses, a net loss of $2.47 million, and net loss per share of $0.28 and it had about $212,000 of cash assets on its books as on September 30th.

Access RDI's Xenetic Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=XBIO

Our Actionable Research on Prana Biotechnology Limited (NASDAQ: PRAN) and Xenetic Biosciences Inc. (NASDAQ: XBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at http://www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Original post:
Prana Biotechnology and Xenetic Biosciences Expand Their Product Promotion - Yahoo Finance

This entry was posted on March 31, 2017 at 3:42 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |